Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2003 1
2004 2
2007 1
2008 1
2010 1
2012 1
2013 1
2014 2
2015 2
2016 2
2017 2
2019 1
2021 1
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.
Balmaña J, Fasching PA, Couch FJ, Delaloge S, Labidi-Galy I, O'Shaughnessy J, Park YH, Eisen AF, You B, Bourgeois H, Gonçalves A, Kemp Z, Swampillai A, Jankowski T, Sohn JH, Poddubskaya E, Mukhametshina G, Aksoy S, Timcheva CV, Park-Simon TW, Antón-Torres A, John E, Baria K, Gibson I, Gelmon KA; LUCY investigators. Balmaña J, et al. Breast Cancer Res Treat. 2024 Apr;204(2):237-248. doi: 10.1007/s10549-023-07165-x. Epub 2023 Dec 19. Breast Cancer Res Treat. 2024. PMID: 38112922 Free PMC article. Clinical Trial.
A large octupole magnetic trap for research with atomic hydrogen.
Ahokas J, Semakin A, Järvinen J, Hanski O, Laptiyenko A, Dvornichenko V, Salonen K, Burkley Z, Crivelli P, Golovizin A, Nesvizhevsky V, Nez F, Yzombard P, Widmann E, Vasiliev S. Ahokas J, et al. Among authors: dvornichenko v. Rev Sci Instrum. 2022 Feb 1;93(2):023201. doi: 10.1063/5.0070037. Rev Sci Instrum. 2022. PMID: 35232145
Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.
Gelmon KA, Fasching PA, Couch FJ, Balmaña J, Delaloge S, Labidi-Galy I, Bennett J, McCutcheon S, Walker G, O'Shaughnessy J; Collaborating Investigators. Gelmon KA, et al. Eur J Cancer. 2021 Jul;152:68-77. doi: 10.1016/j.ejca.2021.03.029. Epub 2021 Jun 1. Eur J Cancer. 2021. PMID: 34087573 Free article. Clinical Trial.
Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study.
Pivot X, Gligorov J, Müller V, Curigliano G, Knoop A, Verma S, Jenkins V, Scotto N, Osborne S, Fallowfield L; PrefHer Study Group. Pivot X, et al. Ann Oncol. 2014 Oct;25(10):1979-1987. doi: 10.1093/annonc/mdu364. Epub 2014 Jul 28. Ann Oncol. 2014. PMID: 25070545 Free article. Clinical Trial.
Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors.
Ponomarenko DM, Klimova ID, Chapygina YA, Dvornichenko VV, Zhukova NV, Orlova RV, Manikhas GM, Zyryanov AV, Burkhanova LA, Badrtdinova II, Oshchepkov BN, Filippova EV, Orlov SV, Kolesnikov SI, Sufianov AA, Baum SR, Zaitzeva OY, Komissarov AB, Grudinin MP, Kiselev OI, Tsyb AF, Venanzi F, Shcherbinina V, Chursov A, Gabai VL, Shneider AM. Ponomarenko DM, et al. Among authors: dvornichenko vv. Oncotarget. 2017 Mar 25;8(32):53730-53739. doi: 10.18632/oncotarget.16574. eCollection 2017 Aug 8. Oncotarget. 2017. PMID: 28881846 Free PMC article.
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.
Gligorov J, Ataseven B, Verrill M, De Laurentiis M, Jung KH, Azim HA, Al-Sakaff N, Lauer S, Shing M, Pivot X; SafeHer Study Group. Gligorov J, et al. Eur J Cancer. 2017 Sep;82:237-246. doi: 10.1016/j.ejca.2017.05.010. Epub 2017 Jun 16. Eur J Cancer. 2017. PMID: 28625777 Clinical Trial.
Five-year disease-free survival among stage II-IV breast cancer patients receiving FAC and AC chemotherapy in phase II clinical trials of Panagen.
Proskurina AS, Gvozdeva TS, Potter EA, Dolgova EV, Orishchenko KE, Nikolin VP, Popova NA, Sidorov SV, Chernykh ER, Ostanin AA, Leplina OY, Dvornichenko VV, Ponomarenko DM, Soldatova GS, Varaksin NA, Ryabicheva TG, Uchakin PN, Rogachev VA, Shurdov MA, Bogachev SS. Proskurina AS, et al. Among authors: dvornichenko vv. BMC Cancer. 2016 Aug 18;16:651. doi: 10.1186/s12885-016-2711-5. BMC Cancer. 2016. PMID: 27538465 Free PMC article. Clinical Trial.
[Ethnic aspects of hereditary breast cancer in the region of Siberia].
Cherdyntseva NV, Pisareva LF, Ivanova AA, Panferova YV, Malinovskaya EA, Odintsova IN, Doroshenko AV, Gervas PA, Slonimskaya EM, Shivit-ool AA, Dvornichenko VV, Choinzonov YL. Cherdyntseva NV, et al. Among authors: dvornichenko vv. Vestn Ross Akad Med Nauk. 2014;(11-12):72-9. doi: 10.15690/vramn.v69i11-12.1186. Vestn Ross Akad Med Nauk. 2014. PMID: 25971130 Russian.
Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer.
Proskurina AS, Gvozdeva TS, Alyamkina EA, Dolgova EV, Orishchenko KE, Nikolin VP, Popova NA, Sidorov SV, Chernykh ER, Ostanin AA, Leplina OY, Dvornichenko VV, Ponomarenko DM, Soldatova GS, Varaksin NA, Ryabicheva TG, Uchakin PN, Zagrebelniy SN, Rogachev VA, Bogachev SS, Shurdov MA. Proskurina AS, et al. Among authors: dvornichenko vv. BMC Cancer. 2015 Mar 13;15:122. doi: 10.1186/s12885-015-1142-z. BMC Cancer. 2015. PMID: 25886605 Free PMC article. Clinical Trial.
[Pharmacokinetics of essentiale N].
Morikov DD, Gorbachev VI, Dvornichenko VV, Semibratova VA, Mikhaĭlov SA. Morikov DD, et al. Among authors: dvornichenko vv. Eksp Klin Farmakol. 2010 Jan;73(1):26-9. Eksp Klin Farmakol. 2010. PMID: 20184285 Russian.
21 results